Myriad Genetics Statistics
Total Valuation
Myriad Genetics has a market cap or net worth of $304.17 million. The enterprise value is $399.47 million.
| Market Cap | 304.17M |
| Enterprise Value | 399.47M |
Important Dates
The last earnings date was Thursday, July 30, 2026, after market close.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Myriad Genetics has 95.65 million shares outstanding. The number of shares has increased by 2.46% in one year.
| Current Share Class | 95.65M |
| Shares Outstanding | 95.65M |
| Shares Change (YoY) | +2.46% |
| Shares Change (QoQ) | +1.17% |
| Owned by Insiders (%) | 3.79% |
| Owned by Institutions (%) | 80.52% |
| Float | 79.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.38 |
| Forward PS | 0.37 |
| PB Ratio | 1.00 |
| P/TBV Ratio | 2.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 39.50 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.69.
| Current Ratio | 2.21 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.01 |
Financial Efficiency
Return on equity (ROE) is -32.54% and return on invested capital (ROIC) is -21.97%.
| Return on Equity (ROE) | -32.54% |
| Return on Assets (ROA) | -8.59% |
| Return on Invested Capital (ROIC) | -21.97% |
| Return on Capital Employed (ROCE) | -19.40% |
| Weighted Average Cost of Capital (WACC) | 10.45% |
| Revenue Per Employee | $298,741 |
| Profits Per Employee | -$41,704 |
| Employee Count | 2,700 |
| Asset Turnover | 1.23 |
| Inventory Turnover | 8.48 |
Taxes
In the past 12 months, Myriad Genetics has paid $800,000 in taxes.
| Income Tax | 800,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.83% in the last 52 weeks. The beta is 1.67, so Myriad Genetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.67 |
| 52-Week Price Change | -17.83% |
| 50-Day Moving Average | 4.98 |
| 200-Day Moving Average | 5.50 |
| Relative Strength Index (RSI) | 27.52 |
| Average Volume (20 Days) | 2,343,674 |
Short Selling Information
The latest short interest is 8.01 million, so 8.37% of the outstanding shares have been sold short.
| Short Interest | 8.01M |
| Short Previous Month | 8.56M |
| Short % of Shares Out | 8.37% |
| Short % of Float | 10.02% |
| Short Ratio (days to cover) | 5.24 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of $806.60 million and -$112.60 million in losses. Loss per share was -$1.20.
| Revenue | 806.60M |
| Gross Profit | 555.20M |
| Operating Income | -90.50M |
| Pretax Income | -111.80M |
| Net Income | -112.60M |
| EBITDA | -48.40M |
| EBIT | -98.60M |
| Loss Per Share | -$1.20 |
Balance Sheet
The company has $115.20 million in cash and $210.50 million in debt, with a net cash position of -$95.30 million or -$1.00 per share.
| Cash & Cash Equivalents | 115.20M |
| Total Debt | 210.50M |
| Net Cash | -95.30M |
| Net Cash Per Share | -$1.00 |
| Equity (Book Value) | 303.90M |
| Book Value Per Share | 3.18 |
| Working Capital | 158.30M |
Cash Flow
In the last 12 months, operating cash flow was $7.70 million and capital expenditures -$15.00 million, giving a free cash flow of -$7.30 million.
| Operating Cash Flow | 7.70M |
| Capital Expenditures | -15.00M |
| Depreciation & Amortization | 50.20M |
| Net Borrowing | 64.90M |
| Free Cash Flow | -7.30M |
| FCF Per Share | -$0.08 |
Margins
Gross margin is 68.83%, with operating and profit margins of -11.22% and -13.96%.
| Gross Margin | 68.83% |
| Operating Margin | -11.22% |
| Pretax Margin | -13.86% |
| Profit Margin | -13.96% |
| EBITDA Margin | -6.00% |
| EBIT Margin | -12.22% |
| FCF Margin | n/a |
Dividends & Yields
Myriad Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.46% |
| Shareholder Yield | -2.46% |
| Earnings Yield | -37.02% |
| FCF Yield | -2.40% |
Analyst Forecast
The average price target for Myriad Genetics is $5.39, which is 69.50% higher than the current price. The consensus rating is "Hold".
| Price Target | $5.39 |
| Price Target Difference | 69.50% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 3.10% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Myriad Genetics has an Altman Z-Score of -0.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.58 |
| Piotroski F-Score | 4 |